You can buy or sell ARWR and other stocks, options, ETFs, and crypto commission-free!
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. Read More The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
52 Week High
52 Week Low
Simply Wall StMar 21
Is Arrowhead Pharmaceuticals, Inc.’s (NASDAQ:ARWR) CEO Salary Justified?
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider the growth in the business. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. This method should give us information to assess how appropriately the company pays the CEO. View our latest analysis for Arrowhead Pharmaceuticals H...
Seeking AlphaMar 11
Arrowhead Pharmaceuticals begins dosing in phase 1 study of ARO-APOC3
Arrowhead Pharmaceuticals (NASDAQ:ARWR) has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based investigational medicine targeting Apolipoprotein C-III (apoC-III) being developed for the treatment of hypertriglyceridemia.
The Motley FoolMar 11
Here's Why Arrowhead Pharmaceuticals Gained 38.2% in February
What happened Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) rose more than 38% last month, according to data from S&P Global Market Intelligence. The incredible rise was catalyzed by fiscal first-quarter 2019 operating results, highlighted by a licensing deal with Johnson & Johnson subsidiary Janssen. Of course, it will take many years before investors know whether the collaboration will live up to its potential. That might help to explain why shares of Arrowhead Pharmaceuticals have dropped 6% since ...
Expected May 7, After Hours